Pharma RSS Digest - 2026-05-05
Overview
Two regulatory milestones this week address graft-versus-host disease, a serious complication following allogeneic stem cell transplantation. Cellenkos secured FDA clearance to advance an off-the-shelf regulatory T cell therapy into Phase 1b/2a for steroid-refractory GVHD, while Australia granted first-in-class approval for NIKTIMVO (axatilimab) in chronic GVHD—marking the first non-US authorization since the US FDA cleared it in 2024. Both developments highlight intensifying interest in novel mechanisms for GVHD, where survival rates remain dire for patients who fail front-line steroids. The timing matters: these patients typically have no durable options beyond second-line immunosuppression, creating pressure for new therapeutic approaches. With limited overlap in patient populations (acute/steroid-refractory versus chronic), these stories collectively expand the treatment landscape rather than compete.
Key Developments
Cellenkos wins FDA IND clearance for CK0802 in steroid-refractory GVHD. The agency cleared the investigational new drug application, allowing Cellenkos to begin a Phase 1b/2a trial of CK0802, an off-the-shelf cord blood-derived regulatory T cell therapy. The multicenter trial will evaluate safety and overall response rate at Day 29, with enrollment planned for H2 2026 and data readout in early 2027. CK0802's multi-mechanism approach—suppressing inflammatory cytokines, consuming IL-2, and neutralizing antigen-presenting cells—distinguishes it from broad immunosuppression. The therapy's three-year shelf life and no HLA matching requirement address the urgent timeline these patients face; current two-year survival for steroid-refractory GVHD is approximately 30%. This milestone validates Cellenkos' CRANE manufacturing platform and clears the path for clinical validation in a population with no effective long-lasting treatments. Watch for trial enrollment pace and any preliminary safety signals ahead of the 2027 data readout.
Australia approves NIKTIMVO as first-in-class anti-CSF-1R antibody for chronic GVHD. The TGA granted Priority Review approval on May 3, 2026, making Australia the first country to authorize NIKTIMVO (axatilimab) since US FDA approval in August 2024. The therapy is indicated for adult and pediatric patients (at least 6 years old, at least 40 kg) after failure of at least two prior systemic therapies. Australian researchers from QIMR Berghofer originated the scientific discovery starting in 2014. The pivotal AGAVE-201 trial demonstrated a 74% overall response rate, with 60% of patients maintaining response at 12 months. Specialised Therapeutics is exploring PBS reimbursement, which will determine actual patient access timelines. The novel CSF-1R mechanism targets inflammation and fibrosis drivers throughout the body, offering a new pathway for patients where nearly 50% require at least three different therapies. Watch for PBS reimbursement decisions and ongoing combination trials with ruxolitinib that could expand frontline use.
Watchlist
- No additional stories met relevance thresholds for today's digest. [link]